Farnesyltransferase inhibitors: Promises and realities

Current Opinion in Pharmacology

Volumn 2, Issue 4, 2002, Pages 388-393

  Cox, Adrienne D ^a   Der, Channing J ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; FARNESYL TRANS TRANSFERASE; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; RHOB GUANINE NUCLEOTIDE BINDING PROTEIN; TAXANE DERIVATIVE; TRASTUZUMAB; ENZYME INHIBITOR; TRANSFERASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; ENZYME INHIBITION; GLIOMA; HUMAN; LEUKEMIA; LUNG NON SMALL CELL CANCER; ONCOGENE C H RAS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; ENZYMOLOGY; METABOLISM; METHODOLOGY; NEOPLASM; ONCOGENE RAS; PHYSIOLOGY; REVIEW;

ALKYL AND ARYL TRANSFERASES; ANIMALS; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; GENES, RAS; HUMANS; NEOPLASMS;

EID: 0036667388     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(02)00181-9     Document Type: Review

References (64)

1. Understanding Ras: 'It ain't over 'til it's over'
2. Farnesyltransferase inhibitors and cancer treatment: Targeting simply Ras?
3. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras
4. Loss of oncogenic ras expression does not correlate with loss of tumorigenicity in human cells
5. Essential role for oncogenic Ras in tumour maintenance
6. RAS inhibitors: Potential for cancer therapeutics
7. Enzymology and biology of CaaX protein prenylation
8. Protein prenylation: From discovery to prospects for cancer treatment
9. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development
10. Farnesyltransferase inhibitors: Targeting the molecular basis of cancer
11. Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: Important mechanistic and bench to bedside issues
12. Non-peptidic prenyltransferase inhibitors: Diverse structural classes and surprising anti-cancer mechanisms
13. Farnesyltransferase inhibitors: Potential role in the treatment of cancer
14. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines
15. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors
16. Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I
17. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo
18. Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells
19. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts
20. Evaluation of farnesyl: Protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models
21. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice
22. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis
23. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor
24. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro
25. A peptidomimetic inhibitor of farnesyl: Protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines
26. Farnesyltransferase inhibitors: Mechanism and applications
27. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors
28. RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage
29. Farnesyltransferase inhibition causes morphological reversion of ras- transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton
30. The ras-related gene rhoB is an immediate-early gene inducible by v-Fps, epidermal growth factor, and platelet-derived growth factor in rat fibroblasts
31. Post-translational modifications of p21rho proteins
32. CAAX geranylgeranyl transferase transfers farnesyl as efficiently as geranylgeranyl to RhoB
33. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB
34. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB
35. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice
36. RhoB is transcriptionally induced by farnesyltransferase and geranylgeranyltransferase I inhibitors: Induction of RhoB does not correlate with human cancer cell growth inhibition
37. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules
38. The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells
39. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines
40. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones
41. Prenylation-dependent association of Ki-Ras with microtubules. Evidence for a role in subcellular trafficking
42. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
43. Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment
44. Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents
45. Current status of clinical trials of farnesyltransferase inhibitors
46. Comparison of potential markers of farnesyltransferase inhibition
47. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia
48. Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies
49. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial
50. Isotype-specific Ras.GTP levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status
51. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: Combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine
52. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines
53. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo
54. A phase I/II study of the farnesyl transferase inhibitor (FTI) SCH66336 (Ionafarnib) with paclitaxel in taxane-refractory/resistant patients with non-small cell lung cancer (NSCLC): Final report
55. A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662 in combination with paclitaxel and carobplatin in patients with advanced cancer
56. MEK inhibition enhances paclitaxel-induced tumor apoptosis
57. The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras
58. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts
59. Rational therapeutic intervention in cancer: Kinases as drug targets
60. The effects of protein farnesyltransferase inhibitors on trypanosomatids: Inhibition of protein farnesylation and cell growth
61. Peptidomimetic inhibitors of protein farnesyltransferase show potent antimalarial activity
62. Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo
63. Discovery of a novel Raf kinase inhibitor
64. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo